12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Brickell Biotech, Signum Dermatologix Inc. deal

Last December, Brickell terminated an April 2012 deal with Signum (formerly Argyle Therapeutics Inc.) granting Brickell exclusive, worldwide rights to develop and commercialize SIG990 for dermatology indications. According to...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >